(Q39173251)

9 September 2017

title

Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases (English)

1 reference

9 September 2017

1 reference

Yuichi Honma

1

1 reference

9 September 2017

Satoshi Shimizu

series ordinal

2

1 reference

9 September 2017

Tetsuo Takehara

series ordinal

3

1 reference

9 September 2017

Masaru Harada

series ordinal

4

1 reference

9 September 2017

publication date

31 March 2013

1 reference

Journal of Gastroenterology

9 September 2017

published in

1 reference

9 September 2017

volume

49

1 reference

9 September 2017

issue

3

1 reference

9 September 2017

page(s)

517-526

1 reference

9 September 2017

cites work

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Strategies for the management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

The proteasome and proteasome inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Transplantation of highly differentiated immortalized human hepatocytes to treat acute liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Autophagy modulates keratin-containing inclusion formation and apoptosis in cell culture in a context-dependent fashion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Insulin-like growth factor-I stimulates H4II rat hepatoma cell proliferation: dominant role of PI-3'K/Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Apoptosis generates stable fragments of human type I keratins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Abnormal structure and expression of p53 gene in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Functions of the MAPK family in vertebrate-development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Apoptosis signaling kinases: from stress response to health outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

Molecularly targeted therapy in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0796-Z

10.1007/S00535-013-0796-Z

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference